| Project/Area Number |
20390328
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
NISHIMURA Tsunehiko Kyoto Prefectural University of Medicine, 医学研究科, 教授 (70237733)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAGAMI Takuji 京都府立医科大学, 医学研究科, 講師 (10257537)
OKUYAMA Chio 京都府立医科大学, 医学研究科, 講師 (40347464)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2010: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2009: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2008: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|
|---|
| Keywords | 分子イメージング / 肝細胞増殖因子(HGF) / 血管新生 / 虚血 / 腫瘍 / 虚血性心疾患 / 腫瘍性疾患 / HGF / 虚血性疾患 |
|---|
| Research Abstract |
[Purpose]c-Met, the specific receptor for hepatocyte growth factor (HGF), has been attracting interest as an important target for the development of treatments for tumors and ischemic diseases. Since imaging c-Met at the cell surface may provide useful information for diagnosing the degree of malignancy and deciding on treatment policy in tumors, and in deciding on sites for effective administration of therapeutic agents in ischemic diseases, our aim in this study was to develop a molecular imaging agent that targeted c-Met.
The basic structure of the probe consists of the 73-amino-acid polypeptide (HGF [11-83]) sequence of the α-chain N-terminal of HGF, which contains the heparin binding site, and we used ^<125>I-labeled and ^<123>I-labeled polypeptides to evaluate the probe.
Retention of heparin-binding activity and c-Met-binding activity by the labeled probes was confirmed in vitro by using the heparin-column method and c-Met-expressing cancer cells. High accumulation of the labeled probes was observed in the xenograft model implanted with c-Met-expressing cancer cells, and accumulation was observed in the infarct boundary region, where c-Met expression is said to be increased, in the myocardial ischemia model.
Because this probe enables non-invasive imaging of c-Met expression in tumors and ischemic diseases, it seems that it will be useful for clinical diagnosis and monitoring treatment, and that it will be able to contribute to promoting the development of drugs and methods of treatment that target c-Met.
|
